Introduction
============

Experimental perturbations of biological systems, such as genetic mutation and chemical exposure, have been used as powerful approaches to deepen our systems-level understanding of biological processes and to discover unprecedented biological phenomena ([@b20]). In particular, perturbations by chemical probes provide broader applications not only for analysis of complex systems but also for intentional manipulations of these systems, e.g., a medicine is a small molecule designed for the purpose of clinical therapy that can actively manipulate biological systems from disordered to well-ordered states. Unfortunately, the number of well-characterized chemical probes is highly limited, which has bottlenecked their wide range of application.

The set of all possible small organic molecules, referred to as chemical space, has been estimated to consist of more than 10^60^ compounds ([@b4]). Chemical space is as vast as the diversity of biological systems, and the vastness of the two domains creates difficulty in comprehensive understanding of the interface between chemical space and biological systems ([@b23]; [@b36]). Recently, chemical genomics has emerged as a promising area of research applicable to exploration of novel bioactive molecules, and researchers are currently striving toward the identification of all possible ligands for all target protein families ([@b46]). Large-scale data sets of compound--protein interactions (CPIs) are being collected, and chemical genomics studies have shown that patterns of protein--ligand interactions are too diverse to be understood as simple one-to-one events. For example, multiple structurally different compounds have been shown to bind the same protein or express similar biological activities ([@b5]; [@b49]). In other cases, one drug has been shown to affect multiple targets from different protein families ([@b24]; [@b33]). This phenomenon, termed polypharmacology, is thought to be one critical cause of adverse drug effects ([@b12]). Therefore, an integrative understanding of multiple interactions among chemical and biological components beyond a one-compound/one-target simplification could open up new opportunities in drug development, but the need to develop appropriate data mining methods for characterizing and visualizing the full complexity of interactions between chemical space and biological systems is urgent ([@b32]). Recently, mining of multiple CPI data sets has been used to identify new protein targets for known drugs and thereby predict unreported polypharmacology ([@b19]). However, this approach only identifies additional targets for known drugs. No existing screening approach has so far succeeded in identifying novel bioactive compounds using multiple interactions among compounds and target proteins, and the potential application of analysis of multiple CPIs to identify novel bioactive molecules remains unknown.

High-throughput screening (HTS) and computational screening have greatly aided in the identification of early lead compounds for drug discovery. However, the large numbers of assays required for HTS to identify drugs that target multiple proteins render this process very costly and time-consuming. Therefore, interest in using *in silico* strategies for screening has been increasing. The most common computational approaches, ligand-based virtual screening (LBVS) and structure-based virtual screening (SBVS; [@b31]; [@b29]; [@b27]; [Figure 1A](#f1){ref-type="fig"}), have been used for practical drug development. Unfortunately, these methods have important limitations. LBVS aims to identify molecules that are very similar to known active molecules and generally has difficulty identifying compounds with novel structural scaffolds that differ from reference molecules. Attempts to scaffold-hop using LBVS are prone to identification of increased numbers of false positives ([@b5]). Therefore, the primary objective of virtual screening, reduction of the number of candidate compounds to be assayed, remains unachievable using this method. The other popular strategy, SBVS, is constrained by the number of three-dimensional crystallographic structures available and, more importantly, by the difficulty of accurately simulating molecular docking processes for targets, including membrane-spanning G-protein-coupled receptors (GPCRs). To circumvent these limitations, we have shown that a new computational screening strategy, chemical genomics-based virtual screening (CGBVS), has the potential to identify novel, scaffold-hopping compounds and assess their polypharmacology by using a machine-learning method to recognize conserved molecular patterns in comprehensive CPI data sets.

Results
=======

Theoretical framework for CGBVS
-------------------------------

The CGBVS strategy is made up of five steps: CPI data collection, descriptor calculation, representation of interaction vectors, predictive model construction using training data sets, and predictions from test data ([Figure 1A](#f1){ref-type="fig"} and [Supplementary Figure S1](#S1){ref-type="supplementary-material"}). Importantly, step 1, the construction of a data set of chemical structures and protein sequences for known CPIs, does not require the three-dimensional protein structures needed for SBVS. We chose GPCRs, important pharmaceutical targets ([@b13]), as our first target proteins for virtual ligand screening. In total, 5207 CPIs (including 317 GPCRs and 866 ligands) retrieved from the GLIDA database ([@b30]) were used as experimental data ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). In step 2, compound structures and protein sequences were converted into numerical descriptors using 929-dimensional and 400-dimensional feature vectors, respectively. A wide variety of chemical descriptors was used to describe the substructures, as well as the physicochemical and molecular properties of the small molecules. Descriptors for protein sequences were created using a string kernel (see Materials and methods section and [Supplementary information](#S1){ref-type="supplementary-material"} for details). These descriptors were used to construct chemical or biological spaces, in which decreasing distance between vectors corresponded to increasing similarity of compound structures or protein sequences. In step 3, we represented multiple CPI patterns by concatenating these chemical and protein descriptors (in 929+400 dimensions). Using these interaction vectors, we could quantify the similarity of molecular interactions for compound--protein pairs, despite the fact that the ligand and protein similarity maps differed substantially ([@b18]). In step 4, concatenated vectors for CPI pairs (positive samples) and non-interacting pairs (negative samples) were input into a support vector machine (SVM; [@b43]), an established machine-learning technique widely applied to pattern-recognition problems ([@b39]; [@b40]). Using training sets, an SVM classifier was generated as a hyperplane dividing positive and negative samples into two distinct classes representing interaction and non-interaction. By mapping the samples into high-dimensional feature space using a nonlinear kernel function, samples that were linearly inseparable in the original input space could be linearly separated in the feature space. As a nonlinear SVM can extract patterns from data sets with nonlinear characteristics, non-intuitive interaction rules can be obtained from multiple CPI patterns, creating the potential to identify novel CPIs. In the final step, the SVM classifier constructed using training sets was applied to test data. Along with providing simple yes/no outputs, the calculated prediction scores also ranked all test compound--GPCR pairs in the order of binding probability.

Computational evaluation of CGBVS
---------------------------------

To evaluate the predictive value of CGBVS, we compared its performance with that of LBVS methodologies using respective data sets of 5207 interacting and non-interacting pairs. The performance of each method was tested by repeating fivefold cross-validations 20 times. CGBVS performed with a considerably higher accuracy (91.9±0.3%) than LBVS (84.4±0.3%, at best). We also recorded the number of true-positive interactions as a function of false positives and plotted receiver operating characteristic (ROC) curves ([@b11]), as shown in [Figure 1B](#f1){ref-type="fig"} and [Supplementary Table S2](#S1){ref-type="supplementary-material"}. ROC analysis revealed that CGBVS performed better than all LBVS methods in terms of the score ranking of CPI pairs.

Recently, the crystal structure of the β2-adrenergic receptor (ADRB2) has been determined ([@b2]; [@b35]). Therefore, we were able to compare CGBVS and SBVS in a retrospective virtual screening based on the human ADRB2 using a representative docking program, Glide ([@b10]). For CGBVS, we constructed a predictive model based on 5167 CPI pairs, excluding 40 known ADRB2-related CPIs to avoid any bias in favor of CGBVS during the machine-learning step. Using both methods, we predicted scores for the same 866 known GPCR ligands, including the 40 known ADRB2 ligands as positive controls. We asked whether the scores for these 40 known positive compounds were higher than scores for other compounds. [Figure 1C](#f1){ref-type="fig"} and [Supplementary Table S3](#S1){ref-type="supplementary-material"} show that CGBVS provided higher enrichment factors (EFs) and hit rates than did SBVS. These results suggest that CGBVS is more successful than conventional approaches for prediction of CPIs.

Polypharmacological interactions for ADRB2
------------------------------------------

We also evaluated the ability of the CGBVS method to predict the polypharmacology of ADRB2 by attempting to identify novel ADRB2 ligands from the above ligand data set. As an established, well-studied pharmaceutical target ([@b45]), we expected that novel ADRB2 ligands would be difficult to find, and that searching for novel scaffolds for such a well-known target would be a stringent assessment of the predictive ability of CGBVS. After training an SVM classifier using all 5207 CPIs, we ranked the prediction scores for the interactions of 826 reported GPCR ligands (excluding the 40 known ADRB2 ligands) with ADRB2, and then analyzed the 50 highest-ranked compounds in greater detail. To complement the less-than-comprehensive binding data available in the original GLIDA database, a literature search was performed using SciFinder ([@b44]) and PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>). This search identified 15 of the top 50 compounds as known ADRB2 ligands. Importantly, these compounds were identified as ligands of other GPCRs, not of ADRB2, in training sets used in the machine-learning step. ADRB2 ligands already reported in the literature were excluded from analysis, but the remainder were tested in *in vitro* binding assays. From the remaining 35 ligands, 21 were commercially available. Of these 21, 11 were not previously reported, but were discovered to bind to ADRB2 ([Figure 2A](#f2){ref-type="fig"} and [Supplementary Table S5](#S1){ref-type="supplementary-material"}). These compounds included ligands for the acetylcholine, serotonin, dopamine, and neuropeptide Y receptors ([Figure 2E](#f2){ref-type="fig"}), indicating the presence of potential polypharmacological interactions with ADRB2.

To substantiate the novelty of the ligands identified by CGBVS, we compared the predictive scores estimated by the three virtual screening approaches (CGBVS, LBVS, and SBVS). We used 26 (orange and green dots in [Figure 2B--D](#f2){ref-type="fig"}) of the top 50 compounds predicted by CGBVS that had ligand activity, but that had not been used in the training data set, to evaluate the other methods. As shown in [Figure 2B and D](#f2){ref-type="fig"}, the known ADRB2 ligands (orange dots) clustered with the highest scores on the LBVS axis, whereas most of the other active compounds identified (green dots) fell outside the top 50 scores. Active compounds (red, orange, and green) were widely scattered along the SBVS axis ([Figure 2C and D](#f2){ref-type="fig"}), and only six were found in the top 50 SBVS scores. This was consistent with the known limitations of LBVS in identification of novel structures and of SBVS in accurate scoring. [Figure 2B--D](#f2){ref-type="fig"} shows that use of CGBVS resulted in the identification of the majority of the novel active compounds (green dots), few of which were identified by LBVS or SBVS. Four of these compounds (**1**--**4** in [Table I](#t1){ref-type="table"} and [Supplementary Table S4](#S1){ref-type="supplementary-material"}) contained novel scaffolds compared with known ADRB2 agonists (catecholamine or isoprenaline derivatives) or ADRB2 antagonists (arylalkylamine derivatives). Notably, these compounds included a neuropeptide Y-type 1 receptor (NPY1R) antagonist (**1**). This observation suggests that only CGBVS could identify this unexpected cross-reaction for a ligand developed as a target to a peptidergic receptor that has low protein homology to ADRB2 ([Figure 2E](#f2){ref-type="fig"}).

Polypharmacology map of the GPCR family
---------------------------------------

To identify possible polypharmacological relationships among GPCRs, we constructed polypharmacology maps, first based on multiple interactions between GPCRs and their ligands predicted by CGBVS, and second based on previously reported interactions ([Figure 3](#f3){ref-type="fig"}). CGBVS predicted many unexpected multiple interactions between GPCRs and ligands, including, interestingly, interactions shared by members of distantly related subfamilies. (See [Supplementary Figure S2](#S1){ref-type="supplementary-material"} for a correlation map of ligands and orphan GPCRs with no known ligands.) To better understand the propensity for ligand promiscuity, we extracted chemical substructures characteristic of the putatively promiscuous ligands ([Supplementary Figure S3](#S1){ref-type="supplementary-material"}), as described in the [Supplementary information](#S1){ref-type="supplementary-material"}. This analysis has shown that tertiary amine and sulfur-containing heterocycles are recurring substructures in the promiscuous ligands when compared with selective ligands ([Supplementary Table S6](#S1){ref-type="supplementary-material"}). For example, these substructures are typically seen in antidepressants used to treat depression and anxiety disorders, which interact promiscuously with a range of dopamine and serotonin receptors ([@b38]). This observation suggests that the ligands containing such substructures can be non-selective.

Unlike CGBVS, SBVS cannot predict CPIs for multiple GPCRs, because only limited three-dimensional structural information is available. LBVS is applicable only to targets with known reference ligands and is therefore unsuitable for identifying polypharmacological interactions, particularly between distantly related GPCRs ([Supplementary Figure S4](#S1){ref-type="supplementary-material"}). The cross-reactivity predictions provided by CGBVS also offer a promising approach for scaffold hopping in drug discovery. For example, many small ligands for non-peptidergic GPCRs were predicted to interact with peptidergic GPCRs as well, indicating that CGBVS has further potential in the discovery of novel non-peptidergic compounds for peptidergic receptors by using these small ligands as reference molecules.

GPCR ligand screening
---------------------

Although preliminary results indicated that CGBVS was useful for identifying polypharmacological relationships among ligands for the GPCR family, all of the analyzed compounds were known GPCR ligands and, therefore, represent a very limited number of examples within the vastness of chemical space. The true value of CGBVS in lead discovery must be tested by assessing whether this method can identify scaffold-hopping lead compounds from a set of compounds that is structurally more diverse. To assess this ability, we analyzed 11 500 compounds from the Bionet chemical library (Key Organics Ltd, Cornwall, UK) to predict compounds likely to bind to two GPCRs from different subfamilies, ADRB2 and NPY1R ([Supplementary Table S7](#S1){ref-type="supplementary-material"}).

The 30 highest-scoring compounds for ADRB2 were tested in calcium mobilization assays, in which nine compounds (hit rate=30%) exhibited either half-maximal effective concentrations (EC~50~) or half-maximal inhibitory concentrations (IC~50~) between 0.7 nM and 65 μM. These results suggest that CGBVS is highly capable of mining of general chemical libraries ([Figure 4A and B](#f4){ref-type="fig"}, [Supplementary Figure S5A and B](#S1){ref-type="supplementary-material"}, and [Supplementary Table S8A](#S1){ref-type="supplementary-material"}). For NPY1R, the 20 highest-scoring compounds were tested in cAMP assays. Of these compounds, three (hit rate=15%) exhibited agonist activity with EC~50~ values of 16, 16, and 63 μM ([Figure 4C](#f4){ref-type="fig"}, [Supplementary Figure S5C and D](#S1){ref-type="supplementary-material"}, and [Supplementary Table S8B](#S1){ref-type="supplementary-material"}).

Despite the fact that these EC~50~ values were in the micromolar range, CGBVS could prove highly useful for lead screening in drug development, as the lead-screening stage is distinct from the optimization stage. For lead screening, it is important to identify bioactive compounds with diverse, novel structures, rather than compounds with extremely high activities in the nanomolar range, because lead candidates are subsequently structurally optimized to generate higher activity in the lead-optimization process.

Evaluation of ligand scaffold hopping
-------------------------------------

We next wanted to evaluate the extent of scaffold hopping achieved in the identification of these novel ligands. However, so far no explicit definition of scaffold hopping exists. Therefore, we began by establishing definitive criteria for scaffold hopping through analysis of the structural relationships between pairs of newly identified active compounds and known ligands in the training data set by calculating their maximum common substructures (MCSs). The number of constituent atoms and bonds in the MCS is typically used as a measure of structural similarity between two molecules. We first calculated MCSs for each Bionet active compound against all of the GPCR ligands in the training data set. Because known GPCR ligands have diverse molecular scaffolds, we selected a single ligand with the largest MCS value (max-MCS) among all the calculated MCSs as the most relevant structure for each active compound (shown in the middle column of [Figure 4D](#f4){ref-type="fig"}). For comparison, we also selected one reference ligand exhibiting the max-MCS from the subset of the training data specific for ADRB2 and NPY1R (shown in the right column of [Figure 4D](#f4){ref-type="fig"}). When the two max-MCSs (shown as the red colored substructures of [Figure 4D](#f4){ref-type="fig"}) contained in these two selected ligands did not overlap, the newly identified active compound in the pair was deemed to have undergone scaffold hopping. This can be a useful criterion for screening lead compounds.

We performed scaffold-hopping analysis after having defined the criterion. For example, compound **5** (2,5-dimethyl-1-(2,2,4-trimethyl-2,3-dihydro-1-benzofuran-7-yl)-1H-pyrrole), which showed weak ADRB2 agonist activity ([Figure 4A](#f4){ref-type="fig"}), did not exhibit overlapping substructure between the max-MCSs of codeine (**6**) or iodocyanopindolol (**7**; [Figure 4D](#f4){ref-type="fig"}), which were selected from all the GPCRs and ADRB2 ligand sets, respectively. Therefore, compound **5** was categorized as representative of scaffold hopping. Indeed, the seven active compounds (**5**, **9**, **28**--**32**), including scaffold-hopped compound **5**, identified as ADRB2 ligands did not contain an oxypropanolamine moiety, an established constituent of β-adrenergic blockers ([Supplementary Tables S9 and S10A](#S1){ref-type="supplementary-material"}). No biological activities have been reported for four (**5**, **28**, **29**, and **30**) of these compounds, whereas ADRB2 activities of the rest compounds (**9**, **31**, and **32**) have not been reported previously (see [Supplementary information](#S1){ref-type="supplementary-material"} for details). In contrast, compounds **8** (Sandoz-21-009) and **33** (1-\[(3-methoxypropyl)amino\]-3-\[(2-methyl-1H-indol-4-yl)oxy\]-2-propanol) both showed strong ADRB2 antagonist activity and had max-MCSs that overlapped with that of iodocyanopindolol (**7**), a known ADRB2 ligand ([Figure 4D](#f4){ref-type="fig"} and [Supplementary Figure S9A](#S1){ref-type="supplementary-material"}). These compounds were, therefore, categorized as non-hopping, although these were originally reported as serotonin receptor ligands and were thus not included in the training data set for ADRB2. Indeed, this max-MCS contained a representative moiety of β-adrenergic blockers ([Supplementary Table S9](#S1){ref-type="supplementary-material"}). Compounds, such as this example with heavily overlapping MCSs, could likely be identified using LBVS. Nevertheless, max-MCS profiling analysis confirmed the reliability of our criteria for scaffold hopping, the accuracy of predictions, and the reliability of the *in vitro* assays. Furthermore, we identified the three novel active compounds for NPY1R that have not previously been known to exhibit biological activity. Of these compounds, compounds **12** (ethyl 1-(4-chlorophenyl)-4-\[(4-methoxybenzyl)amino\]-3-methyl-1H-pyrazolo\[3,4-b\]pyridine-5-carboxylate) and **34** (ethyl 4-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazolo\[3,4-b\]pyridine-5-carboxylate) included examples of scaffold hopping ([Figure 4D](#f4){ref-type="fig"} and [Supplementary Figure S9B](#S1){ref-type="supplementary-material"}).

Overall, CGBVS identified compounds for both GPCRs analyzed that exhibited scaffold hopping, indicating that CGBVS can use this characteristic to rationally predict novel lead compounds, a crucial and very difficult step in drug discovery. This feature of CGBVS is critically different from existing predictive methods, such as LBVS, which depend on similarities between test and reference ligands, and focus on a single protein or highly homologous proteins. In particular, CGBVS is useful for targets with undefined ligands, because this method can use CPIs with target proteins that exhibit lower levels of homology.

Application of CGBVS to kinase inhibitor screening
--------------------------------------------------

Having demonstrated that CGBVS is a valuable strategy for predicting CPIs for GPCRs, we also wanted to show the general utility of this method for other target proteins. Therefore, we selected the protein kinase family, another popular chemotherapeutic target ([@b26]), for the application of CGBVS. A CGBVS model for the kinase family was constructed using a training data set of 15 616 CPI samples (including 143 kinases and their 8830 inhibitors) from the GVK Biosciences Pvt Ltd., (Hyderabad, India) kinase inhibitor database ([Supplementary Table S11](#S1){ref-type="supplementary-material"}). Similar to the GPCR results, polypharmacological predictions for the kinases indicated many possible multiple interactions between kinases and their ligands ([Supplementary Figure S6](#S1){ref-type="supplementary-material"}). The analysis of ligand promiscuity has shown that iodophenyl and polycyclic aromatic groups (containing five-membered heterocycles) are characteristic of the putatively promiscuous ligands ([Supplementary Figure S7](#S1){ref-type="supplementary-material"} and [Supplementary Table S12](#S1){ref-type="supplementary-material"}). In particular, polycyclic aromatic compounds are likely to interact across kinase subfamilies in a manner reminiscent of staurosporine, a well-known promiscuous inhibitor ([@b17]).

We focused on two protein kinases, the epidermal growth factor receptor (EGFR) tyrosine kinase and the cyclin-dependent kinase 2 (CDK2) serine/threonine kinase. We first compared CGBVS with LBVS and SBVS by making predictions using a validation data set that was designed for evaluation of docking programs ([@b14]). For both kinases, CGBVS was able to identify true inhibitors within the top-ranked compounds more effectively than the LBVS and SBVS methods ([Supplementary Figure S8](#S1){ref-type="supplementary-material"}).

We then made prospective predictions for EGFR and CDK2 from the 11 500 Bionet compounds and selected the 20 highest-scoring compounds for experimental verification ([Supplementary Table S7](#S1){ref-type="supplementary-material"}). For EGFR, the off-chip mobility shift assay revealed that 5 of the 20 compounds (hit rate=25%) ranked by CGBVS were inhibitors, with IC~50~ values between 0.014 and 13 μM ([Figure 5A](#f5){ref-type="fig"}, [Supplementary Figure S5E](#S1){ref-type="supplementary-material"} and [Supplementary Table S13A](#S1){ref-type="supplementary-material"}). However, MCS analysis suggested that these compounds did not exhibit scaffold hopping ([Figure 5C](#f5){ref-type="fig"} and [Supplementary Figure S9C](#S1){ref-type="supplementary-material"}). Indeed, the max-MCSs of four of the active compounds (**18**, **21**, **35**, and **36**) for EGFR were quinazoline derivatives ([Supplementary Tables S9 and S10B](#S1){ref-type="supplementary-material"}), which are well-characterized EGFR inhibitors that include the antitumor agent gefitinib. Compound **18** (6,7-dimethoxy-*N*-phenyl-4-quinazolinamine) was shown to act as an EGFR inhibitor. Although compounds **35** (7-chloro-*N*-(3-methoxybenzyl)-4-quinazolinamine) and **36** (6,7-dimethoxy-*N*-(2-thienylmethyl)-4-quinazolinamine) were known to inhibit other proteins such as NOD1 and STAT, their inhibitory activities for EGFR have not been reported. No biological activities have been reported for the remaining two compounds **21** (*N*-{2-\[(4-chlorophenyl)sulfanyl\]ethyl}-6,7-dimethoxy-4-quinazolinamine) and **37** (2-{\[4-(2-chloroacetyl)-1H-pyrrol-2-yl\]methylene}malononitrile).

For CDK2, 2 of the 20 compounds (hit rate=10%) identified had IC~50~ values of 4.9 and 19 μM in the off-chip mobility shift assay ([Figure 5B](#f5){ref-type="fig"}, [Supplementary Figure S5F](#S1){ref-type="supplementary-material"} and [Supplementary Table S13B](#S1){ref-type="supplementary-material"}), and bioactivity of these two compounds also has not been reported previously. One active compound, **23** (\[2-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo\[2,1-b\]\[1,3\]benzothiazol-3-yl\]methanol), was an example of scaffold hopping ([Figure 5C](#f5){ref-type="fig"}). This structure shared the max-MCS of the imidazothiazole moiety with compound **24 (**2-methyl-6-\[6-(6-methyl-pyridin-2-yl)-imidazo\[2,1-b\]thiazol-5-yl\]-3a,7a-dihydro-benzooxazole), a known inhibitor of transforming growth factor-β receptor type 1 tyrosine kinase, unlike CDK2 serine/threonine kinase ([Supplementary Table S10B](#S1){ref-type="supplementary-material"}).

To assess prospective prediction performance of CGBVS versus LBVS and SBVS, we have performed additional experimental validation of the prediction results from LBVS and SBVS for both EGFR and CDK2. Along with the validation protocol for CGBVS, the off-chip mobility shift assays confirmed the bioactivities of the 20 highest-scoring Bionet compounds that were selected by LBVS and SBVS. Consequently, inhibitors were identified by LBVS for neither EGFR nor CDK2 ([Supplementary Figure S10A and B](#S1){ref-type="supplementary-material"}, and [Supplementary Table S14](#S1){ref-type="supplementary-material"}). SBVS identified one EGFR inhibitor (IC~50~=0.73 μM) and one CDK2 inhibitor (IC~50~=26 μM), but neither exhibited scaffold hopping ([Supplementary Figure S10C--G](#S1){ref-type="supplementary-material"} and [Supplementary Table S15](#S1){ref-type="supplementary-material"}). The hit rate of SBVS was 5% (1 hit out of 20 at 10 μM), consistent with the hit rate of SBVS previously reported ([@b41]). As CGBVS exhibited 25 and 10% hit rates for EGFR and CDK2, respectively, the prediction performance of CGBVS was superior to those of existing methods (LBVS and SBVS) for the kinase family as well. These results indicate that CGBVS not only achieves higher hit rates but also predicts ligands with scaffolds different from known ligands in the case of protein kinases, suggesting that CGBVS is applicable to the identification of novel bioactive compounds for multiple protein families.

Discussion
==========

Whereas a critical first step in drug development is the identification of compounds with novel scaffolds, the next crucial step is assessment of selectivity. Information regarding the novelty and selectivity of lead candidates obtained by virtual screening can accelerate the subsequent lead-optimization stage of drug development. A paradigmatic advantage of CGBVS is the incorporation of multiple CPIs, numerically represented as vector descriptors, which integrates both chemical structures and protein sequence data. In contrast, LBVS uses only chemical descriptors in the feature vector. This difference appears to provide CGBVS with a relatively high ability to predict ligand binding to multiple proteins (a measure of selectivity), while allowing scaffold hopping through the use of CPIs. In fact, we observed a concomitant loss of predictive performance when the number of elements for protein vectors was reduced ([Supplementary Figure S11](#S1){ref-type="supplementary-material"}). The difference in the selectivity predictions of CGBVS and LBVS can be explained by the absence of vector descriptors for proteins in LBVS and the related lack of CPI data reflecting ligand recognition. Machine learning with protein data sets also enabled CGBVS to identify compounds that exhibited scaffold hopping because CPIs could be subdivided into chemical substructures and amino acid interactions, on which SBVS relies. In CGBVS, CPIs were described as amino acid versus chemical structure-derived feature vectors. CGBVS predictions are based on extraction of conserved patterns from subdivided interaction vectors involving both proteins and their corresponding ligands. Our successful identification of novel, scaffold-hopping ligands indicates that these conserved patterns included as yet undetermined signatures in the multiple CPIs captured.

Recently, computational approaches conceptually similar to our CGBVS approach have been proposed ([@b6]; [@b15]; [@b47]). However, these studies were limited in scope by the fact that they focused on computational validation through retrospective prediction and lacked experimental verification of the concept. Therefore, the practical utility and general applicability of these methods, specifically aimed at novel lead identification, are questionable.

Our present study has demonstrated that chemical genomics data are of immense practical use for lead discovery. Importantly, in further comparative analyses of the virtual screening of 11 500 Bionet compounds, the novel compounds that we identified using CGBVS were not in the high-scoring range using LBVS or SBVS ([Supplementary Figure S12](#S1){ref-type="supplementary-material"}). Combining CGBVS with conventional methods, such as SBVS and LBVS, can significantly enhance the power of *in silico* strategies.

In the present form, as a learning machine, we used a SVM, which models the two class patterns of interacting pairs and non-interacting pairs by using proteins and their ligands. Therefore, the quality of these two types of training data has much effect on the prediction performance. In this study, we used manually curated protein--ligand interaction data sets from the GLIDA and GVK Biosciences databases. However, even curated data sets are likely to contain some factual errors, which tend to reduce the effectiveness of machine-learning methods. Therefore, improvement in the quality and quantity of the training data resource could enhance the prediction accuracy. A frequent hurdle to overcome when using CPI data is the acquisition of reliable data representing non-interacting pairs of ligands and their targets. Our strategy was to generate the same quantity of negative data from unknown interactions as that available for known interactions. The potential drawback is the possible introduction of a small number of false-negative examples in which the ligand does in fact bind to the target. The publication of experimentally confirmed non-interactions would benefit the CGBVS strategy greatly.

Moreover, it is not easy to comprehensively retrieve enough reliable activity information (that is, IC~50~, EC~50~, *K*~i~ value, etc.) about ligands because our available CPI databases consist of heterogeneous experimental results from many researchers who screened different compound sets for their targets of interest using their original bioassay systems. If we could obtain sufficient and non-biased quantitative affinity data and generate a regressor model such as support vector regression, the prediction performance might be further improved.

Although the traditional drug design process focused on designing a single ligand specifically for a single receptor molecule, our results suggest that a systems biology-based 'integrationist mindset\' ([@b34]) is more appropriate for understanding and computing complex systems in some or all of their entirety. Although the integrationist view is a relatively recent approach that drug discovery research has not embraced completely, the view is beginning to receive attention for such research. Recently, drugs that target multiple proteins have been attracting interest for the development of novel effective therapeutics ([@b38]; [@b7]; [@b28]; [@b1]). As a predictive model, CGBVS could provide an important step in the discovery of such multi-target drugs by identifying the group of proteins targeted by a particular ligand, leading to innovation in pharmaceutical researches.

Materials and methods
=====================

CPI data
--------

Data for 5207 ligand--GPCR pairs (including 317 GPCRs and their 866 ligands) with known CPIs were collected from the GLIDA database ([@b30]), and 15 616 inhibitor--kinase pairs (including 143 kinases and their 8830 inhibitors) were collected from the GVK Biosciences kinase inhibitor database. The GLIDA database was constructed from several reliable resources, including IUPHAR-RD ([@b8]), PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>), PubChem ([@b46]), DrugBank ([@b48]), the Ki Database ([@b37]), and MDL ISIS/Base 2.5. Then, we carefully checked each compound against the primary literature to ensure that the chemical structure, target protein name, and binding and activity information were correct. Although the number of GPCR ligands was relatively small, the CPI pairs represent a credible data set because only interactions with relatively high affinities (*K*~i~, EC~50~, and IC~50~\<1 μM) are deposited in the GLIDA database.

Chemical and protein descriptors
--------------------------------

Chemical descriptors were calculated using the DRAGONX program (version 1.2; Talete S.r.l., Milan, Italy). Protein descriptors were calculated from the sequences alone. Specifically, dipeptide composition-based description (a mismatch-allowed spectrum kernel) was used to represent GPCRs, providing 400 dimensions ([@b21]). For kinases, we used descriptors consisting of 1497 features provided by the PROFEAT Webserver ([@b22]). Calculations of these descriptors were applied to the kinase domain, not to full-length sequences. Finally, these descriptor vectors were separately scaled to the range −1 to 1.

SVM calculations
----------------

SVM calculations for CGBVS used a portion of the LIBSVM suite of programs (<http://www.csie.ntu.edu.tw/~cjlin/libsvm>). The parameters of the SVM with the radial basis function kernel were optimized using a grid search.

Retrospective virtual screening for ADRB2 by CGBVS
--------------------------------------------------

A predictive model for ADRB2 was constructed using a 5207-CPI pair data set, but excluding 40 ADRB2-related CPIs, leaving 5167 pairs. The number of predicted compounds was 866 (including the 40 known ligands). We then combined the chemical descriptors for these compounds and the protein descriptors for ADRB2, and predicted the probability of interactions. The ligand prediction was repeated 20 times with different negative sample sets, and the prediction score was set to the maximum probability.

Retrospective virtual screening for ADRB2 by SBVS
-------------------------------------------------

We used the recently published crystal structure of ADRB2 ([@b2]) as a starting model. The ADRB2 structure and the 866 known ligands were prepared for docking simulations using the Protein Preparation Wizard and LigPrep script within Maestro (Schrödinger Inc, Portland, OR), respectively. This protein preparation procedure involved optimizing contacts by changing hydroxyl group orientations, flipping Asn and Gln side chains, and selecting His tautomeric states, followed by refining energy constraints using the OPLS-AA force field. Glide (SP mode) ([@b10]) was used for grid generation and rigid receptor docking of the ligands. During the simulations, five docking models for each ligand were predicted, and the model with the minimum GlideScore was chosen as the final docking structure. SBVS was performed under two conditions: (1) without constraints, and (2) with constrained hydrogen bonding between the compounds and Asp113, a residue previously shown to be crucial for ligand binding ([@b42]). The different screening approaches were evaluated in terms of the hit rate and the EF ([Supplementary Table S3](#S1){ref-type="supplementary-material"}) using the following equations:

where *N*~sampled~ represents the total number of high-scoring compounds and Hits~sampled~ represents the number of active compounds, and

where *N*~total~ represents the total number of compounds in the complete database and Hits~total~ represents the number of active compounds therein. These values were calculated based on the assumption that all compounds reported to interact with ADRB2 were truly active compounds and that those with unknown activity for the target were inactive.

Retrospective virtual screening for kinases
-------------------------------------------

EGFR and CDK2 were chosen for model validation. In total, 15 616 kinase--inhibitor pairs were used to construct a CGBVS model. First, validation data sets from the DUD website (<http://dud.docking.org/>) were used ([@b14]). Compounds duplicated in the training and test data sets were removed from the test data. For comparison, binding free energy data, calculated by DOCK ([@b25]), was downloaded from the DUD site. Grid generation and rigid receptor ligand docking was performed using another SBVS method, GOLD ([@b16]). During simulations, three docking models for each ligand were predicted, and the model with the minimum ChemScore (or Astex Statistical Potential) was chosen as a final docking structure. Prospective predictions were generated for EGFR and CDK2 using 11 500 Bionet compounds (Key Organics Ltd), and the 20 highest-scoring compounds were selected for experimental verification (See [Supplementary Table S7](#S1){ref-type="supplementary-material"} for compound ID, names, and scores, and [Supplementary Data Set 1](#S1){ref-type="supplementary-material"} for chemical structures of the Bionet compounds).

Polypharmacological prediction and prospective virtual screening by CGBVS
-------------------------------------------------------------------------

A prediction model for ADRB2 was constructed for CGBVS as described for retrospective screening, with the exception that all interaction data were included in the training data set. A prediction model for NPY1R was constructed using the 5207 CPI samples and an additional 3106 CPI samples of peptidergic GPCRs from the Integrity database (Prous Science S.A., Tokyo, Japan). Similarly, a prediction model for kinases was constructed using 15 616 CPI samples from the GVK Biosciences kinase inhibitor database. In each case, 11 500 compounds from the Bionet compound set were screened by CGBVS.

MCS identification for active compounds
---------------------------------------

MCSs for each active compound and every GPCR ligand (or kinase inhibitor) in the training data set were calculated using the LibMCS program in the JChem module ([@b3]). A single known ligand with the highest MCS value (max-MCS) was selected as the most relevant structure for each active compound. For comparison, we also selected a compound with the max-MCS compared with known ligands of the test receptor from the training data. Scaffold hopping was defined as the absence of overlaps between these max-MCSs.

Experiments and the other calculations
--------------------------------------

A detailed description of the applied experimental and other computational techniques is given in the [Supplementary information](#S1){ref-type="supplementary-material"}.
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![Overview and performance of CGBVS. (**A**) Comparison of the strategies used for CGBVS, LBVS, and SBVS. CGBVS used multiple CPI data, represented the CPI in vector form, and used SVM for CPI pattern learning. (**B**) ROC curves obtained by fivefold cross-validation using compound--GPCR interactions for the CGBVS (red) and LBVS methods. The best accuracy rate for each method is also shown. NN--PCA (light blue), nearest neighbor (NN) method with the Pearson correlation coefficient in the constructed space using principal component analysis (PCA); NN--TC (navy), NN method with the Tanimoto coefficient (TC); and NN--PCC (purple), NN method with the Pearson correlation coefficient (PCC) in the original space. (**C**) Enrichment curves obtained by the CGBVS and SBVS methods. Glide was used both without constraints and with constrained hydrogen bonding between the compounds and Asp113, a residue known to be crucial for ligand binding to ADRB2 ([@b42]). Information regarding interactions between ADRB2 and its ligands was not used in test set for machine learning for CGBVS.](msb20115-f1){#f1}

![Prediction of ADRB2 ligands. (**A**) Binding curves for 21 of the top 50 compounds ranked by CGBVS available commercially. Pink, BIBP3226 (**1**); purple, granisetron (**2**); dark yellow, tropisetron (**3**); light blue, BW723C86 (**4**) ([Supplementary Table S5](#S1){ref-type="supplementary-material"}); green, 11 active compounds screened (*K*~i~\<100 μM); and blue, inactive compounds. (**B**--**D**) ADRB2 ligand prediction using CGBVS, LBVS (NN-PCA), and SBVS (GlideScore, Asp113). The NN--PCA score indicates the Pearson correlation coefficient between each compound and its nearest ligands in principal component space. Red, ADRB2 ligands; orange, ligands reported in the literature; green, screened active compounds; and blue, inactive compounds. The numbers **1**--**4** are corresponding to BIBP3226 (**1**), granisetron (**2**), tropisetron (**3**), BW723C86 (**4**), respectively. Dotted lines show the score of the fiftieth-ranked compound using each method. (**E**) Polypharmacological relationships of newly identified ADRB2 ligands. Newly identified (green) and known (orange) ADRB2 ligands were mapped on a human GPCR phylogenetic tree ([@b9]). The size of the circles indicates the number of compounds reported to bind to each GPCR on the tree. Target GPCRs of the four compounds **1**--**4** are shown in the circles. 5HT2A, 5-hydroxytryptamine receptor 2A; 5HT2B, 5-hydroxytryptamine receptor 2B; 5HT4R, 5-hydroxytryptamine receptor 4; 5HT5A, 5-hydroxytryptamine receptor 5A; ACM1, acetylcholine receptor M1; ADA1A, alpha 1-adrenergic receptor type A; ADA1B, alpha 1-adrenergic receptor type B; ADA1D, alpha 1-adrenergic receptor type D; ADA2A, alpha 2-adrenergic receptor type A; ADA2B, alpha 2-adrenergic receptor type B; ADA2C, alpha 2-adrenergic receptor type C; ADRB1, beta 1-adrenergic receptor; ADRB3, beta 3-adrenergic receptor; DRD1, dopamine receptor D1; DRD2, dopamine receptor D2; DRD3, dopamine receptor D3; DRD4, dopamine receptor D4.](msb20115-f2){#f2}

![Comparative polypharmacology maps for GPCRs. (**A**) Map of previously reported compound--GPCR interactions. Vertical and horizontal axes represent the compounds and the GPCRs, respectively. The reported CPIs are depicted as red dots. CGBVS used the CPIs as training data. The colored bars along each axis indicate the classes to which the compounds and GPCRs belong. Am, amines; Pep, peptides; PN, prostanoids; Nuc, nucleotides; and Glu, glutamates. (**B**) Map of predicted compound--GPCR interactions based on CGBVS. The CPIs are plotted with colors ranging from blue (low) to red (high), according to prediction scores. (**C**) Comparative polypharmacology map of GPCRs showing the number of shared compounds within a receptor family. The polypharmacology map was constructed as described by [@b33] by plotting the numbers of common ligands for two given receptors. Previously reported and CGBVS-predicted interactions are shown in the upper-left and the lower-right diagonal halves, respectively. Each value indicates the number of common ligands for each GPCR subfamily. For example, 1081 compounds were reported to be ligands for amine receptors that cross-reacted with other amine receptors, and 14 amine receptor ligands were reported to cross-react with peptide receptors.](msb20115-f3){#f3}

![Experimental confirmation of *in vitro* GPCR activity of compounds and their scaffolds screened from a chemical library. Dose--response curves of the top-ranked compounds from the Bionet chemical library for (**A**) ADRB2 agonists, (**B**) ADRB2 antagonists, and (**C**) NPY1R agonists. Inactive compounds (cutoff of 100 μM in EC~50~/IC~50~ value) are not shown. Red lines indicate results for compounds exhibiting scaffold hopping based on the criteria explained in the Results section. Blue lines indicate results from compounds with almost completely overlapping structures. Compounds **29** (*N*-(*tert*-butyl)-*N*′-(4-methoxybenzyl)thiourea), **30** (2-ethyl-2-{\[(2-fluorobenzyl)oxy\]methyl}-5,5-dimethyltetrahydrofuran), and **5** are corresponding to the curves in A from left to right. Compounds **8**, **33**, **30**, **28** (2-\[2,5-dimethyl-4-(morpholinomethyl)phenoxy\]acetamide), **31** (2-(3-isopropoxyphenyl)-1-ethanamine), **9** ((2-aminophenyl)(4-methylphenyl)amine), and **32** (2-morpholino-2-oxoacetohydrazide) are corresponding to the curves in B from left to right. Compounds **12**, **34**, and **15** (diethyl 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-hydroxy-3,5-pyridinedicarboxylate) are corresponding to the curves in C from left to right. (**D**) Max-MCSs between identified active compounds (left) and the most relevant compounds found within the entire training compound data set (center) or within the ligand set of each target protein (right) that exhibited scaffold hopping. The max-MCSs between compounds are indicated in red. The columns 'bioactivity\' and 'ligand\' indicate the existence of publications regarding the active compound: 'bioactivity\' indicates whether a publication has already described that the compound is bioactive; 'ligand\' indicates whether a publication has uncovered the ADBR2/NPY1R ligand activity, having known the compound is bioactive. All identified active compounds are shown in Supplementary Figure S9. See Table I for compound names of the numbered compounds.](msb20115-f4){#f4}

![Experimental confirmation of the *in vitro* kinase activity of compounds and their scaffolds screened from a chemical library. Dose--response curves of the top-ranked compounds from the Bionet chemical library for EGFR tyrosine kinase inhibitor activity (**A**) and CDK2 inhibitor activity (**B**). Inactive compounds (cutoff of 100 μM in IC~50~ value) are not shown. Color of lines in A and B is the same as in [Figure 4](#f4){ref-type="fig"}. Compounds **18**, **36**, **21**, **35**, and **37** are corresponding to the curves in A from left to right. Compounds **26** (\[4-amino-2-(*tert*-butylamino)-1,3-thiazol-5-yl\](4-chlorophenyl)methanone) and **23** are corresponding to the curves in B from left to right. (**C**) Max-MCSs and publication status are similar to [Figure 4](#f4){ref-type="fig"} for the EGFR and CDK2. See [Table I](#t1){ref-type="table"} for compound names of the numbered compounds.](msb20115-f5){#f5}

###### Compound IDs and names (see Supplementary Table S4 for the chemical structures)

  Compound   GLIDA ID   Bionet ID   Compound name
  ---------- ---------- ----------- ----------------------------------------------------------------------------------------------------------------------------
  **1**      L000117                BIBP3226
  **2**      L003700                Granisetron
  **3**      L002023                Tropisetron
  **4**      L000152                BW723C86
  **5**                 MS-2742     2,5-Dimethyl-1-(2,2,4-trimethyl-2,3-dihydro-1-benzofuran-7-yl)-1H-pyrrole
  **6**      L001048                Codeine
  **7**      L000315                Iodocyanopindolol
  **8**      L001311    12L-933     1-(*Tert*-butylamino)-3-\[(2-methyl-1H-indol-4-yl)oxy\]-2-propanol
  **9**                 MS-2807     (2-Aminophenyl)(4-methylphenyl)amine
  **10**     L013420                Phentolamine
  **11**     L001089                Desipramine
  **12**                7W-0360     Ethyl 1-(4-chlorophenyl)-4-\[(4-methoxybenzyl)amino\]-3-methyl-1H-pyrazolo\[3,4-b\]pyridine-5-carboxylate
  **13**     L001167                Cartazolate
  **14**                            3-(6-Aminopyridin-3-yl)-2-(diphenylacetamido)-N-(4-methoxybenzyl)-*N*-methylpropionamide
  **15**                3H-950      Diethyl 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-hydroxy-3,5-pyridinedicarboxylate
  **16**     L000717                Nicergoline
  **17**                            3-Ethyl-5-\[4-(4-fluorophenyl)-4-(6-fluoropyridin-3-yl)- 5-methyl-4,5-dihydro-1H-imidazol-2-yl\]-1-methylpyridin-2(1H)-one
  **18**                11N-058     6,7-Dimethoxy-*N*-phenyl-4-quinazolinamine
  **19**                            1-(5-*Tert*-butyl-isoxazol-3-yl)-3-\[4-(2-chloro-6,7-dimethoxy-quinazolin-4-ylamino)-phenyl\]-urea
  **20**                            5-\[6-Methoxy-7-(pyridin-4-ylmethoxy)-quinazolin-4-ylamino\]-2-methyl-phenol
  **21**                12N-063     *N*-{2-\[(4-chlorophenyl)sulfanyl\]ethyl}-6,7-dimethoxy-4-quinazolinamine
  **22**                            1-(6,7-Dimethoxy-2-pyridin-4-yl-quinazolin-4-ylamino)-indan-2-ol
  **23**                MS-2894     \[2-(4-Fluorophenyl)-5,6,7,8-tetrahydroimidazo\[2,1-b\]\[1,3\]benzothiazol-3-yl\]methanol
  **24**                            2-Methyl-6-\[6-(6-methyl-pyridin-2-yl)-imidazo\[2,1-b\]thiazol-5-yl\]-3a,7a-dihydro-benzooxazole
  **25**                            1-{4-\[4-Amino-5-(2,6-difluoro-benzoyl)-thiazol-2-ylamino\]-piperidin-1-yl}-8-methyl-non-6-en-1-one
  **26**                7N-773      \[4-Amino-2-(*tert*-butylamino)-1,3-thiazol-5-yl\](4-chlorophenyl)methanone
  **27**                            (4-Amino-2-phenylamino-thiazol-5-yl)-(4-chloro-3-methyl-phenyl)-methanone
  **28**                9X-0942     2-\[2,5-Dimethyl-4-(morpholinomethyl)phenoxy\]acetamide
  **29**                2W-0814     *N*-(*tert*-butyl)-*N*′-(4-methoxybenzyl)thiourea
  **30**                MS-0062     2-Ethyl-2-{\[(2-fluorobenzyl)oxy\]methyl}-5,5-dimethyltetrahydrofuran
  **31**                MS-3556     2-(3-Isopropoxyphenyl)-1-ethanamine
  **32**                3F-004      2-Morpholino-2-oxoacetohydrazide
  **33**                1M-918      1-\[(3-Methoxypropyl)amino\]-3-\[(2-methyl-1H-indol-4-yl)oxy\]-2-propanol
  **34**                6W-0328     Ethyl 4-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazolo\[3,4-b\]pyridine-5-carboxylate
  **35**                10N-835     7-Chloro-*N*-(3-methoxybenzyl)-4-quinazolinamine
  **36**                12N-055     6,7-Dimethoxy-*N*-(2-thienylmethyl)-4-quinazolinamine
  **37**                4X-0854     2-{\[4-(2-Chloroacetyl)-1H-pyrrol-2-yl\]methylene}malononitrile
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